September 2010
Volume 51, Issue 9
Free
Cornea  |   September 2010
Lattice Corneal Dystrophy Type IV (p.Leu527Arg) Is Caused by a Founder Mutation of the TGFBI Gene in a Single Japanese Ancestor
Author Affiliations & Notes
  • Hideki Fukuoka
    From the Department of Ophthalmology, Kyoto Prefectural University of Medicine, Kyoto, Japan; and
  • Satoshi Kawasaki
    From the Department of Ophthalmology, Kyoto Prefectural University of Medicine, Kyoto, Japan; and
  • Kenta Yamasaki
    From the Department of Ophthalmology, Kyoto Prefectural University of Medicine, Kyoto, Japan; and
  • Akira Matsuda
    Department of Ophthalmology, Juntendo University, Tokyo, Japan.
  • Akiko Fukumoto
    From the Department of Ophthalmology, Kyoto Prefectural University of Medicine, Kyoto, Japan; and
  • Akira Murakami
    Department of Ophthalmology, Juntendo University, Tokyo, Japan.
  • Shigeru Kinoshita
    From the Department of Ophthalmology, Kyoto Prefectural University of Medicine, Kyoto, Japan; and
  • Corresponding author: Satoshi Kawasaki, Department of Ophthalmology, Kyoto Prefectural University of Medicine, 465 Kajii-cho, Hirokoji-agaru, Kawaramachi-dori, Kamigyo-ku, Kyoto 602-0841, Japan; bluenova@koto.kpu-m.ac.jp
Investigative Ophthalmology & Visual Science September 2010, Vol.51, 4523-4530. doi:https://doi.org/10.1167/iovs.10-5343
  • Views
  • PDF
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Hideki Fukuoka, Satoshi Kawasaki, Kenta Yamasaki, Akira Matsuda, Akiko Fukumoto, Akira Murakami, Shigeru Kinoshita; Lattice Corneal Dystrophy Type IV (p.Leu527Arg) Is Caused by a Founder Mutation of the TGFBI Gene in a Single Japanese Ancestor. Invest. Ophthalmol. Vis. Sci. 2010;51(9):4523-4530. https://doi.org/10.1167/iovs.10-5343.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose.: Lattice corneal dystrophy (LCD) type IV (LCD4) is a late-onset corneal dystrophy with amyloid deposition at the deep stromal layer of cornea. As with other corneal dystrophies, this LCD subtype is also caused by a mutation (p. Leu527Arg) of the transforming growth factor, β-induced (TGFBI) gene. Although LCD type I has been reported worldwide, LCD4 has been reported only in the Japanese population. In the present study, a haplotype analysis was performed to investigate whether this LCD subtype is caused by a founder mutation.

Methods.: Genomic DNA samples were extracted from 13 unrelated patients with LCD4. As a control, genomic DNA samples from 96 normal volunteers were also analyzed. For the haplotype analysis, the samples were amplified by polymerase chain reaction (PCR), TA-cloned, isothermally amplified, and subjected to a 1-base primer extension assay against a mutation site (c.1580T>G) and six known single-nucleotide polymorphisms (SNPs; rs4669, rs2072239, rs7727725, rs17689879, rs6871571, and rs3792900), which are located adjacent to the mutation site.

Results.: The haplotype analysis revealed that all the disease-carrying alleles from the 13 LCD4 patients shared an identical haplotype, whereas non–disease-carrying alleles from the normal volunteers and the LCD4 patients exhibited four haplotypes. There was a statistically significant difference in the haplotype distribution between the disease-carrying and the non–disease-carrying alleles.

Conclusions.: The findings of this study strongly indicate that LCD4 was caused by a founder mutation of the TGFBI gene that occurred in a single Japanese ancestor.

Cornea is one of the most transparent tissues in the body, and a substantial number of genes contribute to the attainment and maintenance of the specific properties of this tissue. 1,2 Recent advances in molecular biology have allowed us to understand corneal physiology and disease at the molecular level. One of the prominent events in this research area is the discovery of the transforming growth factor, β-induced (TGFBI) gene as a causative gene in five classic autosomal dominant corneal dystrophies. 3 Subsequently, other types of inherited corneal dystrophies, such as Meesmann corneal dystrophy (MECD) 4,5 and gelatinous droplike corneal dystrophy (GDLD), 6,7 have been reported. 
Lattice corneal dystrophy (LCD) is characterized by stromal amyloid depositions that typically appear as a network or lattice. LCD type I (LCD1) is one of the five dominant TGFBI-related corneal dystrophies with characteristic latticelike refractile lines within the corneal stroma. 8 Other than this common LCD, several minor ones have been reported in the TGFBI gene (currently designated as Variant LCD in the IC3D classification) that are caused by different mutations. 9 LCD type IV (LCD4, a variant LCD) is one such corneal dystrophy first reported in 1998 as a late-onset LCD with characteristic amyloid depositions located at the deep stromal layer of cornea. 10 Although LCD1 has been reported world-wide, 3,11 LCD4 has been reported only in the Japanese population. 1219 Thus, some researchers have theorized that LCD4 may be caused by a founder mutation that occurred in a Japanese ancestor. 20  
In this study, we performed a haplotype analysis on genomic DNA samples obtained from 13 patients with LCD4 to investigate this theory. We found that all the disease-carrying alleles of the investigated 13 LCD4 patients shared an identical haplotype around its causative mutation, whereas healthy alleles exhibited four haplotypes with no apparent preference. These data strongly suggest that all LCD4 mutations descend from a founder mutation that occurred in a single Japanese ancestor. 
Materials and Methods
Human Samples
Peripheral blood was obtained from 13 patients from 13 unrelated families who had received a clinical diagnosis of LCD4. These 13 patients were 7 men and 6 women, ranging in age from 52 to 83 years (mean age, 69.8). Seven resided in Kyoto, one in Osaka, one in Mie, one in Niigata, one in Kanagawa, and two in Tokyo Prefecture (Fig. 1). Genomic DNA samples from 96 normal Japanese volunteers (48 men and 48 women) were obtained from a research-resource bank (Human Science Research Resource Bank, Osaka, Japan). Written informed consent was obtained from all patients after they were given a detailed explanation of the study protocols. The study adhered to the tenets of the Declaration of Helsinki and was approved by the Institutional Committee for Ethical Issues at Kyoto Prefectural University of Medicine. 
Figure 1.
 
Geographic distribution of the residences of the 13 LCD4 patients. Prefectures of residence are shown in black and marked as 1, Kyoto; 2, Osaka; 3, Mie; 4, Niigata; 5, Kanagawa; and 6, Tokyo.
Figure 1.
 
Geographic distribution of the residences of the 13 LCD4 patients. Prefectures of residence are shown in black and marked as 1, Kyoto; 2, Osaka; 3, Mie; 4, Niigata; 5, Kanagawa; and 6, Tokyo.
Mutation Analysis
Genomic DNA samples were extracted from the peripheral blood of all 13 LCD4 patients by using a commercially available, standard column-based kit (DNeasy Blood & Tissue Kit; Qiagen, GmbH, Hilden, Germany). The samples were then quantitated by the use of a spectrophotometer (NanoDrop; Thermo Fisher Scientific, Inc., Wilmington, DE) and electrophoresed on a 1% agarose gel, to check their integrity. Next, the samples were amplified by polymerase chain reaction (PCR) with primer pairs (Table 1) against the mutation hot spots (exons 4, 11, and 12) of the TGFBI gene. The amplified products were then treated with a mixture of exonuclease I and shrimp alkaline phosphatase (ExoSAP-IT; GE Health Care, Ltd., Little Chalfont, UK) to digest residual dNTP and primer. The amplified products were then subjected to sequencing reaction (BigDye Terminator ver. 3.1 Cycle Sequencing Kit; Applied Biosystems, Inc. [ABI], Foster City, CA), and the products were electrophoresed on an automated sequencer (3130xl Genetic Analyzer; ABI). The sequence data were analyzed through the use of commercially available alignment software (Variant Reporter; ABI). 
Table 1.
 
List of the Oligomers
Table 1.
 
List of the Oligomers
Oligomer Target Purpose Direction Sequence
Exon4_F TGFBI PCR Forward CCCCAGAGGCCATCCCTCCT
Exon4_R TGFBI PCR Reverse CCGGGCAGACGGAGGTCATC
Exon11_F TGFBI PCR Forward CTCGTGGGAGTATAACCAGT
Exon11_R TGFBI PCR Reverse TGGGCAGAAGCTCCACCCGG
Exon12_F TGFBI PCR Forward GACAGGTGACATTTTCTGTGT
Exon12_R TGFBI PCR Reverse GATCACTACTTTAGAAAAATG
Exon13_R TGFBI PCR Reverse GCTGCAACTTGAAGGTTGTG
TGFBI_27889 c.1580 1-Base primer extension Forward TGCCATCCAGTCTGCAGGAC
TGFBI_27929 rs4669 1-Base primer extension Forward TTTTTTTTTTGAAGGAGTCTACACAGTCTT
TGFBI_28010 rs2072239 1-Base primer extension Forward TTTTTTTTTTTTTTGTAAAGACCAACTTAAGTACAC
TGFBI_28238 rs7727725 1-Base primer extension Forward TTTTTTTTTTTTTTTTTTTTTTTTCAGGAACCAGGGAGGTCA
TGFBI_28641 rs17689879 1-Base primer extension Forward TTTTTTTTTTTTTTTTTTTTTTTTTTTTGGCAGGGGATCTAGTGGTTA
TGFBI_28700 rs6871571 1-Base primer extension Forward TTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTCAGCCTGTGTTGGGAGGATT
TGFBI_29257 rs3792900 1-Base primer extension Forward TTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTGTGTTAGAGGTTGGTACAGG
Haplotype Analysis
Genomic DNA samples were amplified by PCR using a primer pair (exon12_F and exon13_R; Table 1) against a genomic region between exon 12 and 13 of the TGFBI gene, which harbors the site of the c.1580T>G mutation and six known SNPs (Fig. 2, Table 2). The amplified products were then electrophoresed on a 1% agarose gel, excised, purified with a commercially available column-based purification kit (Wizard SV Gel and PCR Clean-Up System; Promega, Madison, WI), and ligated to a TA-cloning vector (pGEM-T Easy Vector; Promega). The plasmid vector was transformed into chemically competent Escherichia coli cells (competent high JM-109; Toyobo Co., Ltd., Osaka, Japan) and seeded on a 1% LB agar plate supplemented with IPTG and X-gal for the standard blue-white selection. After 24 hours' incubation, 16 white colonies were picked from each sample and isothermally amplified overnight with a phi29 polymerase-based plasmid amplification kit (Illustra TempliPhi DNA Amplification Kit; GE Health Care). Each of the amplified products was then subjected to a 1-base primer extension assay (SNaPshot; ABI) with seven pooled primers (Table 1) against the sites of the mutation and the six known SNPs. After treatment with shrimp alkaline phosphatase, the assay products were electrophoresed on the automated sequencer, and the data were analyzed with the use of commercially available software (GeneMapper Software; ABI). Because artificial recombination presumably occurring during the PCR amplification and the bacterial transformation is not negligible in this analysis, a Perl-based program (HapTyper.pl) was created to estimate the most probable haplotype pair from the processed data for each sample. 
Figure 2.
 
The genomic structure for the TGFBI gene with sites of mutation and SNPs investigated. Arrows: PCR primers that amplify a fragment containing all the SNP and mutation sites. The physical distance between two neighboring SNPs is also indicated in base lengths at the bottom.
Figure 2.
 
The genomic structure for the TGFBI gene with sites of mutation and SNPs investigated. Arrows: PCR primers that amplify a fragment containing all the SNP and mutation sites. The physical distance between two neighboring SNPs is also indicated in base lengths at the bottom.
Table 2.
 
List of SNPs within the Amplified Region
Table 2.
 
List of SNPs within the Amplified Region
Region rs ID Heterozygosity Sequence
Exon12 rs4669* 0.494 CCTCAACCGGGAAGGAGTCTACACAGTCTT (C/T) GCTCCCACAAATGAAGCCTTCCGAGCCCTG
Intron12 rs2072239* 0.294 TGAGGGATCACTACTTTAGAAAAATGGAGA (C/T) GTGTACTTAAGTTGGTCTTTACCCAAGAGT
Intron12 rs7727725* 0.494 GGAGGATGAGAGCAGGAACCAGGGAGGTCA (A/T) GAGCCTTGGACAAGGGCACAGAACAGCAGC
Intron12 rs17689879* 0.444 GAGGATGTTTGGCAGGGGATCTAGTGGTTA (C/T) GGGTGGCTAAGAAAAATGAGGAAGGTAAGA
Intron12 rs6871571* 0.494 GAGTATCTTGCAGCCTGTGTTGGGAGGATT (A/G) AATAGGATGCCACACACAGGGCCAGGCAGA
Intron12 rs58761304 N.D. GCAGGAATGGGAGTTGCAGTGTTTAGCTCA (G/T) ATGCATGCCTGTGAGAGATGCTTCCACTCT
Intron12 rs3792900* 0.453 TGCATGGGATGTCCTTTCAATATCTCTAAC (A/G) CCTGTACCAACCTCTAACACTCTCTGTCCC
Intron12 rs45583534 0.023 ACTGATGTGGGCTGAAAGGAATGCTGAGAC (A/G) TGACGAGGAGAGATGCTGCGGAGGGAATAT
Intron12 rs41502049 0.076 GAAACATGAGTCATACTCACAGAGGAGTAT (C/G) GATTAACTCCTTCTCAGCAGCCAGGGAGCC
Intron12 rs45474493 0.011 AACCCAGAGGCCAACTGACTGCTGGGGCAG (A/T) TTTGTGGTCATGAACATGTGCTTTGTGTCC
Statistical Analysis
For the identification of the statistical significance in the haplotype distribution between the affected alleles and the nonaffected alleles, χ2 and Fisher's exact tests were performed with commercially available statistical software (SAS ver. 9.1; SAS Institute Inc., Cary, NC). For the calculation of statistical power, R language (R Foundation, Vienna, Austria) was used. 
Results
The enrolled 13 LCD4 patients, except for 1 patient, exhibited similar corneal haze composed of isolated or fused refractile opacities, most of them being dotlike, and some being latticelike. Most important, these depositions were mainly located within the deep stromal layer, which seems to be specific to this disease and of great diagnostic value, as reported previously. Sequencing analysis revealed that all the 13 LCD4 patients enrolled in this study exhibited a substitution mutation (T to G; c.1580T>G), resulting in an amino acid transition from leucine to arginine (p.Leu527Arg; Fig. 3). Only one patient (59-year-old woman) was homozygous for the mutation site, and she exhibited a much more severe corneal phenotype than did other patients heterozygous for the mutation, such as another homozygous LCD4 patient detailed in a previous report. 19 One patient had a heterozygous substitution mutation from A to G at a different nucleotide position (c.1631A>G) that results in an amino acid transition from asparagine to serine (p.Asn544Ser), which has already been reported to be causative of another type of variant LCD. 17,20,21 In this patient, these two mutations were located on different alleles from one another, as determined by subsequence haplotype analysis (data not shown). 
Figure 3.
 
Results of the mutation analysis of the 13 LCD4 patients. Scleral scattering (A) and iris retroillumination (B) demonstrate the corneal opacity in LCD4. The depth of opacity was nearly at the level of Descemet's membrane. Compared with sequence data from normal volunteers (C), LCD4 patients carried a heterozygous (D) or homozygous T-to-G conversion at c.1580 nucleotide position (arrow).
Figure 3.
 
Results of the mutation analysis of the 13 LCD4 patients. Scleral scattering (A) and iris retroillumination (B) demonstrate the corneal opacity in LCD4. The depth of opacity was nearly at the level of Descemet's membrane. Compared with sequence data from normal volunteers (C), LCD4 patients carried a heterozygous (D) or homozygous T-to-G conversion at c.1580 nucleotide position (arrow).
Haplotype analysis was performed to examine whether the combination of the six SNPs, which are close to the c.1580T>G mutation and hence show a strong linkage disequilibrium to that mutation site, was identical among the disease-carrying alleles of the 13 LCD4 patients. As expected, all the 14 (12 heterozygous plus 1 homozygous) disease-carrying alleles found in the patients demonstrated an identical SNP-haplotype (Table 3). Two of the 12 healthy alleles from the patients exhibited the same SNP-haplotype as found in the disease-carrying alleles. Three different haplotypes were also found in the healthy alleles. A random cross section of normal volunteers was also examined to investigate which haplotypes are dominant in the current Japanese population. Among the 96 normal samples, 91 produced data with sufficient quality for the subsequent analysis, but data from the other 5 samples were omitted due to insufficient quality. In the 91 normal samples, four haplotypes were found, which were identical with those found in the healthy alleles of the LCD4 patients. Of those, the mutation-related haplotype (T-G-T-T-A-T) appeared the most abundant (65/182; 35.7%) in the current Japanese population (Table 4). Statistical significance was found (P = 0.00003, χ2 test, or P = 0.00002, Fisher's exact test) in difference between the haplotype distribution in the disease-carrying and the healthy alleles. The statistical power for our enrolled samples was 1 at the 0.05 level of significance. 
Table 3.
 
Results of the Haplotype Analysis
Table 3.
 
Results of the Haplotype Analysis
Patient Allele c.1580 rs4669 rs2072239 rs7727725 rs17689879 rs6871571 rs3792900
LCD4_1 Healthy T C G A C G C
Disease-carrying G T G T T A T
LCD4_2 Healthy T C A A C G C
Disease-carrying G T G T T A T
LCD4_3 Healthy T T G T C A C
Disease-carrying G T G T T A T
LCD4_4 Healthy T C G A C G C
Disease-carrying G T G T T A T
LCD4_5 Healthy T C A A C G C
Disease-carrying G T G T T A T
LCD4_6 Healthy T T G T C A C
Disease-carrying G T G T T A T
LCD4_7 Healthy T T G T T A T
Disease-carrying G T G T T A T
LCD4_8 Healthy T C G A C G C
Disease-carrying G T G T T A T
LCD4_9 Healthy T C A A C G C
Disease-carrying G T G T T A T
LCD4_10 Disease-carrying G T G T T A T
Disease-carrying G T G T T A T
LCD4_11 Healthy T T G T C A C
Disease-carrying G T G T T A T
LCD4_12 Healthy T T G T T A T
Disease-carrying G T G T T A T
LCD4_13 Healthy T T G T C A C
Disease-carrying G T G T T A T
Table 4.
 
Summarization of the Data Obtained by Haplotype Analysis of the 13 LCD4 Patients and the 91 Normal Volunteers
Table 4.
 
Summarization of the Data Obtained by Haplotype Analysis of the 13 LCD4 Patients and the 91 Normal Volunteers
Haplotype Normal Volunteers Healthy Allele LCD4 Patients
Healthy Allele Disease-Carrying Allele
C-A-A-C-G-C 37 3 0
C-G-A-C-G-C 23 3 0
T-G-T-C-A-C 57 4 0
T-G-T-T-A-T 65 2 14
Discussion
Allelic homogeneity is a prominent feature of the TGFBI-related corneal dystrophies. 22,23 This fact can be well explained by two different mechanisms: the first is the presence of mutation hot spots, 24 and the second is a founder mutation. The mutation hot spots are mainly located at cytosine or guanine within CpG dinucleotides. Cytosine within the CpG dinucleotide is frequently modified by methylation (5-methylated cytosine; 5meC) in mammalian cells, mainly for epigenetic regulation. 25 The 5meC can be spontaneously deaminated, thus producing thymine which results in C>T or G>A conversion when the deamination occurs in a sense or antisense strand, respectively. 26 Although a DNA mismatch–repair mechanism normally recognizes and repairs such heteroduplex sites, 27 the conversions are occasionally passed over unnoticed, possibly due to the insufficient stringency of the repair mechanism. Eventually, when such a conversion occurs in a germ-line cell, the C>T or G>A conversions can be inherited over generations. 
Within the spectrum of TGFBI-related corneal dystrophies, LCD1 and granular corneal dystrophy type 1 (GCD1) are caused by the C>T conversion, granular corneal dystrophy type 2 (GCD2, alternatively designated as Avellino corneal dystrophy) and Thiel-Behnke corneal dystrophy (TBCD) 28 are caused by the G>A conversion, with all these conversions occurring at CpG sites (Table 5). Therefore, it is strongly supposed that these four dominant TGFBI-related corneal dystrophies are caused by that mutation mechanism. In actuality, these dystrophies occur at a relatively high frequency in many countries, thus implicating the existence of multiple, independently occurring founders, in different areas of the world. 
Table 5.
 
Suspected Mutation Mechanism for the TGFBI-Related Corneal Dystrophies
Table 5.
 
Suspected Mutation Mechanism for the TGFBI-Related Corneal Dystrophies
Corneal Dystrophy Nucleotide Change Protein Change Mutated at CpG or Non-CpG Site Mutation Mechanism Reported Countries
LCD1 c.370C>T p.Arg124Cys CpG Deamination Brazil, Bulgaria, Chile, China, Czech Republic, France, Germany, Hungary, India, Japan, South Korea, Spain, Switzerland, Thailand, United Kingdom, Ukraine, United States, Vietnam
GCD1 c.1663C>T p.Arg555Trp CpG Deamination China, Czech Republic, France, Germany, Hungary, India, Japan, Mexico, New Zealand, Poland, Spain, Switzerland, Taiwan, Turkey, United Kingdom, Ukraine, United States, Vietnam
GCD2 c.371G>A p.Arg124His CpG Deamination China, France, Germany, Hungary, India, Iran, Japan, South Korea, Spain, Switzerland, United Kingdom, United States, Vietnam
TBCD c.1664G>A p.Arg555Gln CpG Deamination Brazil, China, Czech Republic, France, Hungary, Japan, New Zealand, Switzerland, United Kingdom, United States
RBCD c.371G>T p.Arg124Leu CpG Replication error Brazil, China, Czech Republic, Denmark, France, India, Japan, Switzerland
LCD3A c.1501C>A p.Pro501Thr non-CpG Replication error Japan
LCD4 c.1580T>G p.Leu527Arg non-CpG Replication error Japan
Variant LCD c.1640T>C p.Phe547Ser non-CpG Replication error Hungary
Variant LCD c.1874T>A p.Val625Asp non-CpG Replication error China
Apart from the mutation mechanism, other types of mutations, including non-C>T or non-G>A mutations or C>T or G>A mutations occurring at non-CpG sites, sometimes occur. Such types of mutations seem to be mainly caused by the accidentally occurring replication error during cell division that may escape the proofreading function of DNA polymerase, as well as the DNA mismatch-repair process, with a roughly estimated frequency of 1 in 109 to 1010 base pairs per cell division. 27 Hence, these mutations are predisposed to be much less frequent and tend to become a founder mutation. Other than the four dominant TGFBI-related corneal dystrophies described earlier, those including LCD4 clearly meet the criteria for this mutation mechanism (Table 5). In fact, most of these corneal dystrophies occur infrequently and are reported in only one, or at most, only a few countries. For example, in the Japanese population, founder mutations have been reported in corneal dystrophies of LCD type IIIA 23 (currently designated as variant LCD in the IC3D classification), GCD2, 22 and GDLD with a p.Gln118X mutation. 7 Our current haplotype analysis of the 13 LCD4 patients revealed that all their disease-carrying alleles share an identical SNP-haplotype. Since the residences of the 13 patients were not restricted to a small geographic area, but in fact, extended across six different prefectures in Japan (Fig. 1), such biased data seem to be ascribed, not to the preference of a certain SNP-haplotype that was due to a bias toward their place of residence, but rather to the occurrence of a founder mutation in a Japanese ancestor. We imagine that almost all infrequently occurring corneal dystrophies may have been related to the occurrence of founder mutations. 
One exception to the hypothesis for the occurrence of a mutation among the TGFBI-related corneal dystrophies appears to be Reis-Bückler's corneal dystrophy (RBCD). The mutation of RBCD is located on the same CpG site as that of LCD1 and GCD2 but its substitution is G>T, not C>T or G>A. Therefore, the cause of mutation in RBCD seems to be a simple replication error not a deamination. However, RBCD has been reported in many countries, similar to the other four dominant TGFBI-related corneal dystrophies. Therefore, the exact mechanism for the occurrence of the RBCD mutation cannot be explained by our hypothesis, but it is hoped that it will be elucidated in the future. 
We performed a 1-base primer extension assay for the identification of the SNP-haplotype. The reason we chose that method rather than the standard sequencing analysis is that the former method can be easily multiplexed and hence largely save time and costs compared with the latter method. In addition, a commercially available phi29 polymerase-based, isothermal plasmid amplification procedure has been developed. 29 This procedure is much more time-efficient than the standard plasmid DNA extraction procedure and has been subjected to various applications. 3033 Thus, we examined whether the phi29 polymerase-amplified plasmid DNA can also be used as the template for the 1-base primer extension assay. As is shown in Figure 4, the chromatogram data of this combined assay was of sufficient quality for the identification of each of the SNPs examined in this study. We think that this combined procedure is quite useful for experimentally determining haplotypes. 
Figure 4.
 
Results of the 1-base primer extension assay. Shown are representative chromatogram data for all the observed haplotypes, as indicated at the top left corners. The first base (G or T) is of the site of the mutation (c.1580), not of the SNP. The T-T-G-T-T-A-C haplotype is an artificial product by the recombination of the T-T-G-T-C-A-C and the T-T-G-T-T-A-T haplotypes at the indicated site (square).
Figure 4.
 
Results of the 1-base primer extension assay. Shown are representative chromatogram data for all the observed haplotypes, as indicated at the top left corners. The first base (G or T) is of the site of the mutation (c.1580), not of the SNP. The T-T-G-T-T-A-C haplotype is an artificial product by the recombination of the T-T-G-T-C-A-C and the T-T-G-T-T-A-T haplotypes at the indicated site (square).
We initially expected that data from the 16 plasmids investigated for each sample could be easily divided into one or two haplotype groups without any confusion. However, the actual data were sometimes quite complicated, possibly due to the artificial recombination during the consecutive processes of PCR and bacterial transformation, as reported previously. 34 In that study, a method of eliminating such an artificial recombination was also reported. However, although we performed an additional three-cycle PCR amplification against a 10-times diluted initial PCR product, according to this reconditioning PCR method, the artificial recombination was still observed, possibly due to the insufficiency of the reconditioning PCR. For example, a mutation/SNP-combination T-T-G-T-T-A-C was observed in a normal volunteer who was found to have two haplotypes (T-T-G-T-C-A-C and T-T-G-T-T-A-T; Fig. 4). Therefore, we created a Perl-based software program, to identify the most probable haplotype pair by calculating a score for each of the possible haplotypes estimated from the genotype data of each sample. We carefully reviewed the processed data and found that the software worked properly. We think that this software may be useful for studies conducted in the future that are similar to the present study. 
In summary, our findings indicate that LCD4 was caused by a founder mutation that occurred in a single Japanese ancestor. In addition, we have established a time- and cost-efficient new procedure through the combination of an isothermal amplification of plasmid DNA and a 1-base primer extension assay. We created a Perl-based software program that helps estimate the most probable haplotype pair from blended data hampered by randomly occurring artificial recombinations. We hope that the results of this study, as well as the newly developed procedures, will contribute to the further understanding of the etiology, populational genetics, and pathogenesis of inherited dystrophies of the cornea and of other organs. 
Footnotes
 Supported by Grant-in-Aid 21592238 from the Japanese Ministry of Education, Science, Culture, and Sports, and a grant from the Japanese Ministry of Health, Labor, and Welfare. This work was also supported by a research fund from the Kyoto Foundation for the Promotion of Medical Science.
Footnotes
 Disclosure: H. Fukuoka, None; S. Kawasaki, None; K. Yamasaki, None; A. Matsuda, None; A. Fukumoto, None; A. Murakami, None; S. Kinoshita, None
The authors thank John Bush for reviewing the manuscript and Tatsuo Terashima and Shigeo Kamitsuji for excellent technical advise on the statistical analysis. 
References
Nishida K Adachi W Shimizu-Matsumoto A . A gene expression profile of human corneal epithelium and the isolation of human keratin 12 cDNA. Invest Ophthalmol Vis Sci. 1996;37:1800–1809. [PubMed]
Kinoshita S Adachi W Sotozono C . Characteristics of the human ocular surface epithelium. Prog Retin Eye Res. 2001;20:639–673. [CrossRef] [PubMed]
Munier FL Korvatska E Djemai A . Kerato-epithelin mutations in four 5q31-linked corneal dystrophies. Nat Genet. 1997;15:247–251. [CrossRef] [PubMed]
Irvine AD Corden LD Swensson O . Mutations in cornea-specific keratin K3 or K12 genes cause Meesmann's corneal dystrophy. Nat Genet. 1997;16:184–187. [CrossRef] [PubMed]
Nishida K Honma Y Dota A . Isolation and chromosomal localization of a cornea-specific human keratin 12 gene and detection of four mutations in Meesmann corneal epithelial dystrophy. Am J Hum Genet. 1997;61:1268–1275. [CrossRef] [PubMed]
Tsujikawa M Tsujikawa K Maeda N . Rapid detection of M1S1 mutations by the protein truncation test. Invest Ophthalmol Vis Sci. 2000;41:2466–2468. [PubMed]
Tsujikawa M Kurahashi H Tanaka T . Identification of the gene responsible for gelatinous drop-like corneal dystrophy. Nat Genet. 1999;21:420–423. [CrossRef] [PubMed]
Mannis MJ De Sousa LB Gross RH . The stromal dystrophies. In: Krachmer JH Mannis MJ Holland EJ eds. Cornea. St. Louis, MO: Mosby; 1997:1048–1051.
Weiss JS Moller HU Lisch W . The IC3D classification of the corneal dystrophies. Cornea. 2008;27(suppl 2):S1–S83. [PubMed]
Fujiki K Hotta Y Nakayasu K . A new L527R mutation of the betaIGH3 gene in patients with lattice corneal dystrophy with deep stromal opacities. Hum Genet. 1998;103:286–289. [CrossRef] [PubMed]
Hotta Y Fujiki K Ono K . Arg124Cys mutation of the betaig-h3 bene in a Japanese family with lattice corneal dystrophy type I. Jpn J Ophthalmol. 1998;42:450–455. [CrossRef] [PubMed]
Fujiki K Hotta Y Nakayasu K . Six different mutations of TGFBI (betaig-h3, keratoepithelin) gene found in Japanese corneal dystrophies. Cornea. 2000;19:842–845. [CrossRef] [PubMed]
Fujiki K Nakayasu K Kanai A . Corneal dystrophies in Japan. J Hum Genet. 2001;46:431–435. [CrossRef] [PubMed]
Funayama T Mashima Y Kawashima M Yamada M . Lattice corneal dystrophy type III in patients with a homozygous L527R mutation in the TGFBI gene. Jpn J Ophthalmol. 2006;50:62–64. [CrossRef] [PubMed]
Hirano K Hotta Y Nakamura M Fujiki K Kanai A Yamamoto N . Late-onset form of lattice corneal dystrophy caused by leu527Arg mutation of the TGFBI gene. Cornea. 2001;20:525–529. [CrossRef] [PubMed]
Hirano K Nakamura M Yamamoto N Hotta Y . Geographical feature of lattice corneal dystrophy patients in Aichi Prefecture: an analysis of the TGFBI gene (in Japanese). Nippon Ganka Gakkai Zasshi. 2002;106:352–359. [PubMed]
Kawashima M Yamada M Funayama T Mashima Y . Six cases of late-onset lattice corneal dystrophy associated with gene mutations induced by the transforming growth factor-beta (in Japanese). Nippon Ganka Gakkai Zasshi. 2005;109:93–100. [PubMed]
Nakagawa E Sakimoto T Inada N . Histopathological study of lattice corneal dystrophy with L 527 R mutation of transforming growth factor-beta induced gene (in Japanese). Nippon Ganka Gakkai Zasshi. 2004;108:118–123. [PubMed]
Yamada N Chikama TI Morishige N . Homozygous mutation (L527R) of TGFBI in an individual with lattice corneal dystrophy. Br J Ophthalmol. 2005;89:771–773. [CrossRef] [PubMed]
Mashima Y Yamamoto S Inoue Y . Association of autosomal dominantly inherited corneal dystrophies with BIGH3 gene mutations in Japan. Am J Ophthalmol. 2000;130:516–517. [CrossRef] [PubMed]
Nakagawa Asahina S Fujiki K Enomoto Y Murakami A Kanai A . Case of late onset and isolated lattice corneal dystrophy with Asn544Ser (N544S) mutation of transforming growth factor beta-induced (TGFBI, BIGH3) gene (in Japanese). Nippon Ganka Gakkai Zasshi. 2004;108:618–620. [PubMed]
Tsujikawa K Tsujikawa M Watanabe H . Allelic homogeneity in Avellino corneal dystrophy due to a founder effect. J Hum Genet. 2007;52:92–97. [CrossRef] [PubMed]
Tsujikawa K Tsujikawa M Yamamoto S Fujikado T Tano Y . Allelic homogeneity due to a founder mutation in Japanese patients with lattice corneal dystrophy type IIIA. Am J Med Genet. 2002;113:20–22. [CrossRef] [PubMed]
Korvatska E Munier FL Djemai A . Mutation hot spots in 5q31-linked corneal dystrophies. Am J Hum Genet. 1998;62:320–324. [CrossRef] [PubMed]
Holliday R . DNA methylation and epigenetic inheritance. Philos Trans R Soc Lond B Biol Sci. 1990;326:329–338. [CrossRef] [PubMed]
Cooper DN Youssoufian H . The CpG dinucleotide and human genetic disease. Hum Genet. 1988;78:151–155. [CrossRef] [PubMed]
Hsieh P Yamane K . DNA mismatch repair: molecular mechanism, cancer, and ageing. Mech Ageing Dev. 2008;129:391–407. [CrossRef] [PubMed]
Ridgway AE Akhtar S Munier FL . Ultrastructural and molecular analysis of Bowman's layer corneal dystrophies: an epithelial origin? Invest Ophthalmol Vis Sci. 2000;41:3286–3292. [PubMed]
Nelson JR Cai YC Giesler TL . TempliPhi, phi29 DNA polymerase based rolling circle amplification of templates for DNA sequencing. BioTechniques. 2002;Jun(suppl):44–47.
Li J Zhong W . Typing of multiple single-nucleotide polymorphisms by a microsphere-based rolling circle amplification assay. Anal Chem. 2007;79:9030–9038. [CrossRef] [PubMed]
Hutchison CA3rd Smith HO Pfannkoch C Venter JC . Cell-free cloning using phi29 DNA polymerase. Proc Natl Acad Sci U S A. 2005;102:17332–17336. [CrossRef] [PubMed]
Reddy PS Mahanty S Kaul T Nair S Sopory SK Reddy MK . A high-throughput genome-walking method and its use for cloning unknown flanking sequences. Anal Biochem. 2008;381:248–253. [CrossRef] [PubMed]
Li N Jablonowski C Jin H Zhong W . Stand-alone rolling circle amplification combined with capillary electrophoresis for specific detection of small RNA. Anal Chem. 2009;81:4906–4913. [CrossRef] [PubMed]
Thompson JR Marcelino LA Polz MF . Heteroduplexes in mixed-template amplifications: formation, consequence and elimination by ‘reconditioning PCR’. Nucleic Acids Res. 2002;30:2083–2088. [CrossRef] [PubMed]
Figure 1.
 
Geographic distribution of the residences of the 13 LCD4 patients. Prefectures of residence are shown in black and marked as 1, Kyoto; 2, Osaka; 3, Mie; 4, Niigata; 5, Kanagawa; and 6, Tokyo.
Figure 1.
 
Geographic distribution of the residences of the 13 LCD4 patients. Prefectures of residence are shown in black and marked as 1, Kyoto; 2, Osaka; 3, Mie; 4, Niigata; 5, Kanagawa; and 6, Tokyo.
Figure 2.
 
The genomic structure for the TGFBI gene with sites of mutation and SNPs investigated. Arrows: PCR primers that amplify a fragment containing all the SNP and mutation sites. The physical distance between two neighboring SNPs is also indicated in base lengths at the bottom.
Figure 2.
 
The genomic structure for the TGFBI gene with sites of mutation and SNPs investigated. Arrows: PCR primers that amplify a fragment containing all the SNP and mutation sites. The physical distance between two neighboring SNPs is also indicated in base lengths at the bottom.
Figure 3.
 
Results of the mutation analysis of the 13 LCD4 patients. Scleral scattering (A) and iris retroillumination (B) demonstrate the corneal opacity in LCD4. The depth of opacity was nearly at the level of Descemet's membrane. Compared with sequence data from normal volunteers (C), LCD4 patients carried a heterozygous (D) or homozygous T-to-G conversion at c.1580 nucleotide position (arrow).
Figure 3.
 
Results of the mutation analysis of the 13 LCD4 patients. Scleral scattering (A) and iris retroillumination (B) demonstrate the corneal opacity in LCD4. The depth of opacity was nearly at the level of Descemet's membrane. Compared with sequence data from normal volunteers (C), LCD4 patients carried a heterozygous (D) or homozygous T-to-G conversion at c.1580 nucleotide position (arrow).
Figure 4.
 
Results of the 1-base primer extension assay. Shown are representative chromatogram data for all the observed haplotypes, as indicated at the top left corners. The first base (G or T) is of the site of the mutation (c.1580), not of the SNP. The T-T-G-T-T-A-C haplotype is an artificial product by the recombination of the T-T-G-T-C-A-C and the T-T-G-T-T-A-T haplotypes at the indicated site (square).
Figure 4.
 
Results of the 1-base primer extension assay. Shown are representative chromatogram data for all the observed haplotypes, as indicated at the top left corners. The first base (G or T) is of the site of the mutation (c.1580), not of the SNP. The T-T-G-T-T-A-C haplotype is an artificial product by the recombination of the T-T-G-T-C-A-C and the T-T-G-T-T-A-T haplotypes at the indicated site (square).
Table 1.
 
List of the Oligomers
Table 1.
 
List of the Oligomers
Oligomer Target Purpose Direction Sequence
Exon4_F TGFBI PCR Forward CCCCAGAGGCCATCCCTCCT
Exon4_R TGFBI PCR Reverse CCGGGCAGACGGAGGTCATC
Exon11_F TGFBI PCR Forward CTCGTGGGAGTATAACCAGT
Exon11_R TGFBI PCR Reverse TGGGCAGAAGCTCCACCCGG
Exon12_F TGFBI PCR Forward GACAGGTGACATTTTCTGTGT
Exon12_R TGFBI PCR Reverse GATCACTACTTTAGAAAAATG
Exon13_R TGFBI PCR Reverse GCTGCAACTTGAAGGTTGTG
TGFBI_27889 c.1580 1-Base primer extension Forward TGCCATCCAGTCTGCAGGAC
TGFBI_27929 rs4669 1-Base primer extension Forward TTTTTTTTTTGAAGGAGTCTACACAGTCTT
TGFBI_28010 rs2072239 1-Base primer extension Forward TTTTTTTTTTTTTTGTAAAGACCAACTTAAGTACAC
TGFBI_28238 rs7727725 1-Base primer extension Forward TTTTTTTTTTTTTTTTTTTTTTTTCAGGAACCAGGGAGGTCA
TGFBI_28641 rs17689879 1-Base primer extension Forward TTTTTTTTTTTTTTTTTTTTTTTTTTTTGGCAGGGGATCTAGTGGTTA
TGFBI_28700 rs6871571 1-Base primer extension Forward TTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTCAGCCTGTGTTGGGAGGATT
TGFBI_29257 rs3792900 1-Base primer extension Forward TTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTGTGTTAGAGGTTGGTACAGG
Table 2.
 
List of SNPs within the Amplified Region
Table 2.
 
List of SNPs within the Amplified Region
Region rs ID Heterozygosity Sequence
Exon12 rs4669* 0.494 CCTCAACCGGGAAGGAGTCTACACAGTCTT (C/T) GCTCCCACAAATGAAGCCTTCCGAGCCCTG
Intron12 rs2072239* 0.294 TGAGGGATCACTACTTTAGAAAAATGGAGA (C/T) GTGTACTTAAGTTGGTCTTTACCCAAGAGT
Intron12 rs7727725* 0.494 GGAGGATGAGAGCAGGAACCAGGGAGGTCA (A/T) GAGCCTTGGACAAGGGCACAGAACAGCAGC
Intron12 rs17689879* 0.444 GAGGATGTTTGGCAGGGGATCTAGTGGTTA (C/T) GGGTGGCTAAGAAAAATGAGGAAGGTAAGA
Intron12 rs6871571* 0.494 GAGTATCTTGCAGCCTGTGTTGGGAGGATT (A/G) AATAGGATGCCACACACAGGGCCAGGCAGA
Intron12 rs58761304 N.D. GCAGGAATGGGAGTTGCAGTGTTTAGCTCA (G/T) ATGCATGCCTGTGAGAGATGCTTCCACTCT
Intron12 rs3792900* 0.453 TGCATGGGATGTCCTTTCAATATCTCTAAC (A/G) CCTGTACCAACCTCTAACACTCTCTGTCCC
Intron12 rs45583534 0.023 ACTGATGTGGGCTGAAAGGAATGCTGAGAC (A/G) TGACGAGGAGAGATGCTGCGGAGGGAATAT
Intron12 rs41502049 0.076 GAAACATGAGTCATACTCACAGAGGAGTAT (C/G) GATTAACTCCTTCTCAGCAGCCAGGGAGCC
Intron12 rs45474493 0.011 AACCCAGAGGCCAACTGACTGCTGGGGCAG (A/T) TTTGTGGTCATGAACATGTGCTTTGTGTCC
Table 3.
 
Results of the Haplotype Analysis
Table 3.
 
Results of the Haplotype Analysis
Patient Allele c.1580 rs4669 rs2072239 rs7727725 rs17689879 rs6871571 rs3792900
LCD4_1 Healthy T C G A C G C
Disease-carrying G T G T T A T
LCD4_2 Healthy T C A A C G C
Disease-carrying G T G T T A T
LCD4_3 Healthy T T G T C A C
Disease-carrying G T G T T A T
LCD4_4 Healthy T C G A C G C
Disease-carrying G T G T T A T
LCD4_5 Healthy T C A A C G C
Disease-carrying G T G T T A T
LCD4_6 Healthy T T G T C A C
Disease-carrying G T G T T A T
LCD4_7 Healthy T T G T T A T
Disease-carrying G T G T T A T
LCD4_8 Healthy T C G A C G C
Disease-carrying G T G T T A T
LCD4_9 Healthy T C A A C G C
Disease-carrying G T G T T A T
LCD4_10 Disease-carrying G T G T T A T
Disease-carrying G T G T T A T
LCD4_11 Healthy T T G T C A C
Disease-carrying G T G T T A T
LCD4_12 Healthy T T G T T A T
Disease-carrying G T G T T A T
LCD4_13 Healthy T T G T C A C
Disease-carrying G T G T T A T
Table 4.
 
Summarization of the Data Obtained by Haplotype Analysis of the 13 LCD4 Patients and the 91 Normal Volunteers
Table 4.
 
Summarization of the Data Obtained by Haplotype Analysis of the 13 LCD4 Patients and the 91 Normal Volunteers
Haplotype Normal Volunteers Healthy Allele LCD4 Patients
Healthy Allele Disease-Carrying Allele
C-A-A-C-G-C 37 3 0
C-G-A-C-G-C 23 3 0
T-G-T-C-A-C 57 4 0
T-G-T-T-A-T 65 2 14
Table 5.
 
Suspected Mutation Mechanism for the TGFBI-Related Corneal Dystrophies
Table 5.
 
Suspected Mutation Mechanism for the TGFBI-Related Corneal Dystrophies
Corneal Dystrophy Nucleotide Change Protein Change Mutated at CpG or Non-CpG Site Mutation Mechanism Reported Countries
LCD1 c.370C>T p.Arg124Cys CpG Deamination Brazil, Bulgaria, Chile, China, Czech Republic, France, Germany, Hungary, India, Japan, South Korea, Spain, Switzerland, Thailand, United Kingdom, Ukraine, United States, Vietnam
GCD1 c.1663C>T p.Arg555Trp CpG Deamination China, Czech Republic, France, Germany, Hungary, India, Japan, Mexico, New Zealand, Poland, Spain, Switzerland, Taiwan, Turkey, United Kingdom, Ukraine, United States, Vietnam
GCD2 c.371G>A p.Arg124His CpG Deamination China, France, Germany, Hungary, India, Iran, Japan, South Korea, Spain, Switzerland, United Kingdom, United States, Vietnam
TBCD c.1664G>A p.Arg555Gln CpG Deamination Brazil, China, Czech Republic, France, Hungary, Japan, New Zealand, Switzerland, United Kingdom, United States
RBCD c.371G>T p.Arg124Leu CpG Replication error Brazil, China, Czech Republic, Denmark, France, India, Japan, Switzerland
LCD3A c.1501C>A p.Pro501Thr non-CpG Replication error Japan
LCD4 c.1580T>G p.Leu527Arg non-CpG Replication error Japan
Variant LCD c.1640T>C p.Phe547Ser non-CpG Replication error Hungary
Variant LCD c.1874T>A p.Val625Asp non-CpG Replication error China
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×